Source-grounded facts extracted from Apellis Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Apellis Pharmaceuticals, Inc.: Bylaws amended and restated in their entirety effective at the Effective Time pursuant to the Merger Agreement.
“Pursuant to the terms of the Merger Agreement, effective as of the Effective Time, the Company’s bylaws were amended and restated in their entirety.”
Apellis Pharmaceuticals, Inc.: Certificate of incorporation amended and restated in its entirety effective at the Effective Time pursuant to the Merger Agreement.
“Pursuant to the terms of the Merger Agreement, effective as of the Effective Time, the Company’s certificate of incorporation was amended and restated in its entirety.”
Apellis Pharmaceuticals, Inc. underwent a change of control involving Biogen Inc. for approximately $5.3 billion (closed 2026-05-14).
“in January 2026 and (B) the target performance levels for all other Company PSUs. The aggregate amount to be paid by Purchaser in the Offer and the Merger is approximately $5.3 billion, excluding related fees and expenses and, for the avoidance of doubt, any amounts that may become payable pursuant to the CVRs. Biogen and Purchaser will fund the acquisition of”
Michael Dambach was appointed as Director at Apellis Pharmaceuticals, Inc..
“the director of Purchaser as of immediately prior to the Effective Time, Michael Dambach, became the director of the Company.”
Craig Wheeler resigned as Member of the Board of Directors at Apellis Pharmaceuticals, Inc..
“Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.”
Cedric Francois resigned as Member of the Board of Directors at Apellis Pharmaceuticals, Inc..
“Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.”
Gerald Chan resigned as Member of the Board of Directors at Apellis Pharmaceuticals, Inc..
“Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.”
Keli Walbert resigned as Member of the Board of Directors at Apellis Pharmaceuticals, Inc..
“Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.”
Alec Machiels resigned as Member of the Board of Directors at Apellis Pharmaceuticals, Inc..
“Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.”
A. Sinclair Dunlop resigned as Member of the Board of Directors at Apellis Pharmaceuticals, Inc..
“Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.”
Stephanie Monaghan O’Brien resigned as Member of the Board of Directors at Apellis Pharmaceuticals, Inc..
“Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.”
Paul Fonteyne resigned as Member of the Board of Directors at Apellis Pharmaceuticals, Inc..
“Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.”
Mikael Dolsten resigned as Member of the Board of Directors at Apellis Pharmaceuticals, Inc..
“Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.”
Apellis Pharmaceuticals, Inc. entered into Agreement and Plan of Merger with Biogen Inc. (effective 2026-03-31).
“On March 31, 2026, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Biogen Inc., a Delaware corporation (“Parent”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”).”
Craig A. Wheeler was elected as Director at Apellis Pharmaceuticals, Inc..
“On April 17, 2025, the Board of Directors (the “Board”) of Apellis Pharmaceuticals, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), elected Craig A. Wheeler to the Board as a Class III director to serve until the Annual Meeting of Stockholders to be held in 2026 or until his successor has been duly elected and qualified or until his earlier death, resignation or removal.”
Adam Townsend departed as Chief Operating Officer at Apellis Pharmaceuticals, Inc..
“On January 10, 2025, the Company and Adam Townsend mutually agreed that Mr. Townsend will resign as the Company’s Chief Operating Officer effective as of February 21, 2025 (the “Separation Date”).”
Keli Walbert was elected as Director at Apellis Pharmaceuticals, Inc..
“On January 8, 2025, the Board of Directors (the “Board”) of the Company, upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Keli Walbert to the Board as a Class II director to serve until the Annual Meeting of Stockholders to be held in 2025 or until her successor has been duly elected and qualified or until her earlier death, resignation or removal.”
Apellis Pharmaceuticals, Inc. incurred term loan of up to $475 million with Sixth Street Lending Partners at 3-month Secured Overnight Financing Rate (SOFR) + 5.75% (subject to 1.00% floor) maturing May 13, 2030.
“Street Lending Partners, as the administrative agent and collateral agent for the Lenders. The Financing Agreement provides for a senior secured term loan facility of up to $475 million (the “Credit Facility”), consisting of an initial draw of $375 million at closing and a potential additional $100 million draw at the Company’s option upon satisfaction of a $50”
Apellis Pharmaceuticals, Inc. entered into Financing Agreement with Sixth Street Lending Partners valued at up to $475 million (effective 2024-05-13).
“On May 13, 2024 (the “Closing Date”), Apellis Pharmaceuticals, Inc. (the “Company”) entered into a financing agreement (the “Financing Agreement”) with the guarantors party thereto, the lenders party thereto (the “Lenders”), and Sixth Street Lending Partners, as the administrative agent and collateral agent for the Lenders. The Financing Agreement provides for a senior secured term loan facility of up to $475 million (the “Credit Facility”), consisting of an initial draw of $375 million at closing and a potential additional $100 million draw at the Company’s option upon satisfaction of a $50 million minimum cash requirement and a requirement that the Company’s trailing three-month sales of SYFOVRE were at least $180 million prior to the $100 million draw.”
Apellis Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: revenue $396.6 million.
“For the full year 2023, total revenue was $396.6 million”
Apellis Pharmaceuticals, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $146.4 million.
“Total revenue was $146.4 million for the fourth quarter of 2023”
Adam Townsend was appointed as Chief Operating Officer at Apellis Pharmaceuticals, Inc..
“On January 16, 2024, the Board of Directors of Apellis Pharmaceuticals, Inc. (the “Company”) appointed Adam Townsend, the Company’s Chief Commercial Officer, to serve as the Company’s Chief Operating Officer, effective immediately.”
Apellis Pharmaceuticals, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023.
“Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced preliminary U.S. net product revenues of approximately $138 million for the fourth quarter and approximately $366 million for the full year 2023 for SYFOVRE ® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration and for EMPAVELI ® (pegcetacoplan) for adults with paroxysmal nocturnal hemoglobinuria (PNH).”
Apellis Pharmaceuticals, Inc. terminated Open Market Sale Agreement SM with Jefferies LLC valued at up to $300.0 million (effective 2023-10-31).
“In connection with the entry into the Agreement, on October 31, 2023, the Company terminated its prior Open Market Sale Agreement SM , dated as of January 20, 2022 (the “Prior Agreement”), by and between the Company and Jefferies LLC (“Jefferies”), in accordance with its terms.”
Apellis Pharmaceuticals, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $300.0 million (effective 2023-11-01).
“On November 1, 2023, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Sales Agreement (the “Agreement”) with Cowen and Company, LLC, as agent (“Cowen”), pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share (the “Shares”), from time to time through Cowen (the “Offering”).”
Apellis Pharmaceuticals, Inc. reported third quarter of 2023 results: revenue approximately $74 million.
“Apellis expects approximately $74 million in preliminary U.S. net product revenue for SYFOVRE in the third quarter and approximately $160 million in preliminary total U.S. net product revenue for SYFOVRE since launch in March 2023 through September 30, 2023.”
Apellis Pharmaceuticals, Inc. announced a restructuring with charges of approximately $9 million to $11 million affecting corporate restructuring includes SYFOVRE launch, EMPAVELI reduction, R&D prioritization (approximately 225 employees, or approximately 25% of its current workforce).
“in workforce will be substantially completed in the third quarter of 2023. As a result of the reduction in workforce, the Company estimates that it will incur approximately $9 million to $11 million in costs, substantially all of which are cash expenditures. These costs are anticipated to be incurred primarily in the second half of 2023. The estimate of costs”
Apellis Pharmaceuticals, Inc. reported the second quarter 2023 results: revenue $95.0 million.
“total revenue was $95.0 million for the second quarter of 2023, which consisted of $22.3 million of U.S. net product revenue of EMPAVELI, $67.3 million of U.S. net product revenue of SYFOVRE, and additional licensing and other revenue under the Sobi collaboration.”
Apellis Pharmaceuticals, Inc. shareholders approved Advisory vote on compensation of named executive officers (say-on-pay) at the 2023-06-01 meeting.
“The stockholders of the Company approved the advisory vote on the compensation of the Company’s named executive officers. The results of the stockholders’ non-binding advisory vote with respect to the compensation paid to the Company’s named executive officers were as follows: For Against Abstain Broker Non-Votes 94,979,579 6,659,652 546,457 5,095,730”
Apellis Pharmaceuticals, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-01 meeting.
“The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such ratification were as follows: For Against Abstain Broker Non-Votes 107,213,813 39,783 27,822 —”
Apellis Pharmaceuticals, Inc. shareholders approved Election of class III directors at the 2023-06-01 meeting.
“The stockholders of the Company elected Gerald Chan and Cedric Francois as class III directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2026. The results of the stockholders’ vote with respect to the election of the class III directors were as follows: Name For Withheld Broker Non-Votes Gerald Chan 82,568,712 19,616,976 5,095,730 Cedric Francois 101,552,924 632,764 5,095,730”
Apellis Pharmaceuticals, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C. valued at approximately $333.0 million (effective 2023-02-22).
“On February 22, 2023, Apellis Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C., as representatives of the several underwriters (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 3,174,603 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and, in lieu of Common Stock to investors who so choose, pre-funded warrants (the “Pre-Funded Warrants”) to purchase 2,380,956 shares of Common Stock (the “Warrant Shares”).”
Apellis Pharmaceuticals, Inc. reported FY 2022 results: revenue $65 million.
“Caroline Baumal as Chief Medical Officer (effective Q1 2023) ~$65 million1 in U.S. net product sales Submitted sNDA for PRINCE & 48-week PEGASUS data Submitted sNDA for EMPAVELI injector Completed >800 patient years of systemic dosing2 Progressed late-stage clinical studies with partner Sobi Advanced early-stage”
Caroline Baumal was appointed as Chief Medical Officer at Apellis Pharmaceuticals, Inc..
“Caroline Baumal, M.D. will join the Company as Chief Medical Officer, effective as of January 3, 2023.”
Federico Grossi departed as Chief Medical Officer at Apellis Pharmaceuticals, Inc..
“Federico Grossi, M.D., Ph.D., the Chief Medical Officer of the Company, will be leaving the Company to pursue new career opportunities.”
Jim Chopas was appointed as Vice President, Corporate Controller / Chief Accounting Officer and principal accounting officer at Apellis Pharmaceuticals, Inc..
“On August 24, 2021, the Board of Directors (the “Board”) of Apellis Pharmaceuticals, Inc. (the “Company”) appointed Jim Chopas, as Vice President, Corporate Controller / Chief Accounting Officer and principal accounting officer of the Company, effective as of August 30, 2021 (the “Effective Date”).”
Nicole Perry changed role as Vice President of Accounting and principal accounting officer at Apellis Pharmaceuticals, Inc..
“On August 13, 2021, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Nicole Perry, Vice President of Accounting and principal accounting officer of the Company, agreed that she would transition from the role of principal accounting officer, effective as of August 30, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.